Development of a clinical chemiluminescent immunoassay for serum gpc3 and simultaneous measurements alone with afp and ck19 in diagnosis of hepatocellular Carcinoma

Journal of Clinical Laboratory Analysis

Volumn 29, Issue 2, 2015, Pages 85-93

  Yu, Juan Ping ^a   Xu, Xi Guang ^a   Ma, Rui Juan ^a   Qin, Shi Ni ^a   Wang, Cong Rong ^a   Wang, Xiao Bo ^a   Li, Ming ^a   Li, Ming Song ^a   Ma, Qiang ^a   Xu, Wei Wen ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

Chemiluminescent immunoassay; Glypican 3; Hepatocellular carcinoma

Indexed keywords

ALPHA FETOPROTEIN; ANTIBODY; CARCINOEMBRYONIC ANTIGEN; CYTOKERATIN 19; GLYPICAN 3; GLYPICAN; GPC3 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; ARTICLE; BLOOD SAMPLING; CANCER PATIENT; CHEMILUMINESCENCE ANALYZER; CHEMILUMINESCENCE IMMUNOASSAY; CHEMILUMINESCENCE IMMUNOASSAY KIT; CONTROLLED STUDY; CORRELATION COEFFICIENT; CROSS REACTION; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; HUMAN; IMMUNOFLUORESCENCE ASSAY KIT; LIVER; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PREDICTIVE VALUE; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN STABILITY; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; SERUM; BLOOD; IMMUNOASSAY; LIVER TUMOR; LUMINESCENCE; PROCEDURES;

ALPHA-FETOPROTEINS; CARCINOMA, HEPATOCELLULAR; GLYPICANS; HUMANS; IMMUNOASSAY; KERATIN-19; LIVER NEOPLASMS; LUMINESCENT MEASUREMENTS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 84925260083     PISSN: 08878013     EISSN: 10982825     Source Type: Journal    
DOI: 10.1002/jcla.21733     Document Type: Article

References (29)

1. Wright LM, Kreikemeier JT, Fimmel CJ. A concise review of serum markers for hepatocellular cancer. Cancer Detect Prev 2007;31:35-44.
2. Pilia G, Hughes-Benzie RM, MacKenzie A, et al. Mutations in GPC3, a glypican gene, cause the Simpson-Golabi-Behmel overgrowth syndrome. Nat Genet 1996;12:241-247.
3. Capurro M, Wanless IR, Sherman M, et al. Glypican-3: A novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology 2003;125:89-97.
4. Shirakawa H, Kuronuma T, Nishimura Y, et al. Glypican-3 is a useful diagnostic marker for a component of hepatocellular carcinoma in human liver cancer. Int J Oncol 2009;34:649-656.
5. Zakhary NI, Mohamed MS, Khorshid O, Azer RS, Zayed N. Role of glypican-3 in the early diagnosis of hepatocellular carcinoma among Egyptian patients. J Genet Eng Biotechnol 2012;10:73-79.
6. Filmus J, Capurro M. Glypican-3 and alphafetoprotein as diagnostic tests for hepatocellular carcinoma. Mol Diagn 2004;8:207-212.
7. Qiao SS, Cui ZQ, Gong L, et al. Simultaneous measurements of serum AFP, GPC-3 and HCCR for diagnosing hepatocellular carcinoma. Hepatogastroenterology 2011;58(110-111):1718-1724.
8. Ho M, Kim H. Glypican-3: A new target for cancer immunotherapy. Eur J Cancer 2011;47(3):333-338.
9. Feng M, Gao W, Wang R, et al. Therapeutically targeting glypican-3 via a conformation-specific single-domain antibody in hepatocellular carcinoma. Proc Natl Acad Sci USA 2013;110(12):E1083-E1091.
10. Zhu AX, Gold PJ, El-Khoueiry AB, et al. First-in-man phase I study of GC33, a novel recombinant humanized antibody against glypican-3, in patients with advanced hepatocellular carcinoma. Clin Cancer Res 2013;19(4):920-928.
11. Sawada Y, Yoshikawa T, Nobuoka D, et al. Phase I trial of a glypican-3-derived peptide vaccine for advanced hepatocellular carcinoma: Immunologic evidence and potential for improving overall survival. Clin Cancer Res 2012;18(13):3686-3696.
12. Sturgeon C, Hill R, Hortin GL, Thompson D. Taking a new biomarker into routine use-A perspective from the routine clinical biochemistry laboratory. Proteomics Clin Appl 2010;4(12):892-903
13. Translational research: Getting the message across. Nature 2008;453(7197):839.
14. Zhang Q, Xiao Q, Lin Z, Ying X, Li Z, Lin JM. Development of a competitive radioimmunoassay for glypican-3 and the clinical application in diagnosis of hepatocellular carcinoma. Clin Biochem 2010;43(12):1003-1008.
15. Zhang Q, Chen H, Lin Z, Lin JM. Chemiluminescence enzyme immunoassay based on magnetic nanoparticles for detection of hepatocellular carcinoma marker glypican-3. J Pharm Anal 2011;1(3):166-174.
16. Yasuda E, Kumada T, Toyoda H, et al. Evaluation for clinical utility of GPC3, measured by a commercially available ELISA kit with Glypican-3 (GPC3) antibody, as a serological and histological marker for hepatocellular carcinoma. Hepatol Res 2010;40(5):477-485.
17. Ma RJ, Wang SH, Qin SN, et al. Preparation and characterization of monoclonal antibody against glypican-3. Hybridoma (Larchmt) 2012;31(6):455-461.
18. Yu J P, Ma Q, Zhang B, et al. The initial clinical application of specific antibody against glypican-3 in hepatocellular carcinoma diagnosis. Sci China Life Sci 2013;56(3):234-239.
19. Zhu ZW, Friess H, Wang L, et al. Enhanced glypican-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders. Gut 2001;48:558-564.
20. Sherman M, Scess H, Wang L, et al. Enhanced glypican-3 expression differentiates the majority of hepatocellular carcinomas fromreening for hepatocellular carcinoma. Clin Gastroenterol 2005;19:101-118.
21. Zhou XP, Wang HY, Yang GS, et al. Cloning and expression of MXR7 gene in human HCC tissue. World J Gastroenterol 2000;6:57-60.
22. Petar NG, Mladen IY, Mariana DD. The oncofetal protein glypican-3 is a novel marker of hepatic progenitor/oval cells. Lab Invest 2006;86:1272-1284.
23. Capurro M, Wanless IR, Sherman M, et al. Glypican-3: A novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology 2003;125:89-97.
24. Sakamoto M. Early HCC: Diagnosis and molecular markers. J Gastroenterol 2009;44(Suppl 19):108-111.
25. Wang XY, Degos F, Dubois S, et al. Glypican-3 expression in hepatocellular tumors: Diagnostic value for preneoplastic lesions and hepatocellular carcinomas. Hum Pathol 2006;37:1435-1441.
26. Nakatsura T, Yoshitake Y, Senju S, et al. Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker. Biochem Biophys Res Commun 2003;306:16-25.
27. Yamauchi N, Watanabe A, Hishinuma M, et al. The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma. Mod Pathol 2005;18:1591-1598.
28. Zhang QY, Xiao Q, Lin Z, et al. Development of a competitive radioimmunoassay for glypican-3 and the clinical application in diagnosis of hepatocellular carcinoma. Clin Biochem 2010;43:1003-1008.
29. Xu C, Zhehui Y, Liang Z, et al. A comparison of glypican-3 with alpha-fetoprotein as a serum marker for hepatocellular carcinoma: a meta-analysis. J Cancer Res Clin Oncol 2013;139:1417-1424.